Purpose: Compassionate-use oxaliplatin-paclitaxel was assessed for toxicity and efficacy according to clinical platinum resistance status in cisplatin-carboplatin-pretreated advanced ovarian cancer patients.
Introduction
Since the incorporation of platinum compounds into ovarian cancer (OC) treatment, disease control and survival in advanced OC patients have improved. Singleagent paclitaxel is an active salvage compound, with objective response rates (ORRs) of 14% to 33%, and its combination with cis-/carboplatin in first-line treatment has improved time-related disease-progression parameters [1] .
Oxaliplatin (Eloxatin®), is a new platinum compound with a mechanism of action similar to that of classic platinum compounds, but with a different cytotoxic profile. It appears not to be cross-resistant with cis-/carboplatin in human ovarian cell lines [2, 3] . Oxaliplatin has a characteristic toxicity profile with acute cold-triggered dysesthesias and cumulative neurosensorial toxicity as its principal side effects, but without haematological, renal or auditive toxicity at recommended doses [4] . Single-agent oxaliplatin is active in cisplatin-pretreated or resistant OC, and, combined with cisplatin, displays clinical synergy in heavily pretreated OC patients [5, 6] .
Oxaliplatin and paclitaxel single-agent activity [5, 7] in cisplatin-resistant OC, and their non-overlapping toxicity profiles make them suitable for combination [8] , as was done in a compassionate-use programme with pretreated OC patients. Since both induce peripheral neurotoxicity, this side effect was carefully assessed in cis-/carboplatin-pretreated patients.
Patients and methods

Patient selection
Between June 1994 and July 1998, 37 pretreated OC patients were enrolled in an oxaliplatin individual patient allowance extended-access program. Oxaliplatin was supplied by Sanofi Winthrop upon physician requests. Written information was given to each patient, and treatment was conducted under the prescribing oncologist's responsibility.
Patients were to have confirmed advanced OC, progressed/relapsed after ^ I prior cis-/carboplatin-containing chemotherapy; PS = 2 (WHO), peripheral neurotoxicity = 1 (NCI-CTC), adequate bone marrow (neutrophil count 51500/ml. haemoglobin ^9.5 mg/dl, platelet count > 100,000 /ml), liver (bilirubin ^ 2x upper limit of normal (ULN), AST and ALT =£3x ULN, or ^5 ULN in case of liver metastasis), and renal (creatinine <2x ULN or creatinine clearance >60 ml/min) functions. As this was a compassionate-use program, disease evaluability criteria and eligibility guidelines were not strictly adhered to.
Treatment
Oxaliplatin and paclitaxel were given sequentially on the same day every 3-4 weeks. Oxaliplatin (100-135 mg/m 2 ). and paclitaxel (135-175 mg/m 2 ) dose levels were determined according to number and intensity of prior chemotherapy regimens and residual toxicities. Oxaliplatin was administered i.v. over two or six hours, diluted in 500 ml of 5% dextrose, followed by paclitaxel as a three-hour infusion in 500 ml of 5% glucose. Paclitaxel premedication was 130 mg of prednisolone per os. 12 and 6 hours before treatment administration. I.v. dexchlorpheniramine (5 mg) and ranitidine (150 mg) were administered 30 minutes before paclitaxel. Antiemetics were administered according to center practice. Patients were retrospectively grouped into oxaliplatin-paclitaxel dose levels (DLs) (mg/m 2 ). DL1: 100/135. DL2: 130-135/135, DL3: 100/160-175, DL4: 130-135/160-175.
Toxicity and response evaluation
Toxicities were graded using the NCI-CTC scale Complete blood cell counts were performed weekly. Serum creatinine, blood electrolyte levels and CA 125 serum levels were obtained before each treatment cycle.
Antitumour activity (WHO-UICC) was assessed by clinical examination and imaging techniques An Expert Review Committee (ERC) assessed patients reported by the treatment oncologist as having a response, disease stabilisation 3= 12 weeks' duration, or as non-evaluable (treatment following optimal debulking surgery).
Progression-free survival (PFS) and overall survival (OS) were calculated by the Kaplan-Meier method from the beginning of treatment to disease progression/death, respectively Survival follow-up continued until March 1999. Table 1 presents demographic, pretreatment, disease history and extent characteristics. Nine patients had formerly received carboplatin in high-dose chemotherapy regimens. According to Markman's criteria [9] , 20 patients were refractory to platinum compounds, 16 were sensitive, and 1 unclassified. All treated patients were evaluable for toxicity, while 31 of them had measurable/ evaluable targets for antitumour activity assessment.
Results
Patient characteristics, treatment exposure and toxicity
A total of 209 treatment cycles were given (median: 6 cycles/patient; range: 2-9). Overall median dose intensities: oxaliplatin = 48 mg/m 2 /week; paclitaxel = 35.3 mg/m 2 /week. Median cumulative doses: oxaliplatin = 650 mg/m 2 /patient (range 200-1170); paclitaxel = 960 mg/m 2 /patient (range 300-1575). Table 2 presents toxicity data. Haematological toxicity was moderate, with Grade 3-4 neutropenia in 16% and 13% of cycles, respectively. One patient had two episodes of neutropenia-related fever. Neutropenia episodes were brief. In the nine patients pretreated with high-dose chemotherapy (57 cycles), haematological toxicity was moderate, with grade 3-4 neutropenia in three patients.
Peripheral neurotoxicity was the most common side effect, seen in 94% of patients. The maximum cumulative neurosensory toxicities were grade 2 (12 patients) and 3 (6 patients, NCI-CTC), with four patients experi- encing grade 3 toxicity after a ^ 520 mg/m 2 cumulative oxaliplatin dose, and two patients with cumulative doses between 780 and 1170 mg/m 2 . Of the 28 patients (77%) with neurotoxicity symptoms at treatment discontinuation, and available for ^ 6 months follow-up, 10 (36%) recovered completely by the first follow-up (3-9 months).
Treatment delays and dose modifications
Eleven cycles were delayed because of haematological toxicity, most of them (eight of eleven) for < 2 weeks. One patient discontinuing treatment after two cycles because of grade 3 neurotoxicity (severe myalgia and nail dystrophy) recovered completely.
Eight of one hundred seventy-two (5%) cycles had minor (15%-20%) dose reductions, mostly without specific reasons. (3) 1 (7) 8 (22) 1(12.5) 1 (11) 6 (43) 3 (8) 1(12 5) 2(22) 5 (13.5) 2 (25) 1(11) 1(17) 1 (7) 1 (3) 1 (7) 1 (0 .5) 1(1.5) 32 (16) 4(9) 14(27.5) 3 (10) 11 (16) 5(2.5) 3 (6.5) 2(4) 5 (2 5) 2(4) 1(2) 1(3) 1(1.5) 0.5
1(1.5)
11 (30) 1 (12.5) 5(56) 1 (17) 4 (29) 25 (13) 1 (2) 12(23.5) 2 (6.5) 10(15) 1 (3) 1 (0.5)
For data given by dose level, values are indicated in reference to patients/cycles by dose level. Table 3 summarizes response data. According to the ERC, 15 of the 37 patients had objective responses, yielding an ORR of 41% (95% CI: 25-56). In the 31 evaluable patients, the ORR was 48% (95% CI: 31-66).
Treatment activity
Causes of non-evaluability were: treatment discontinuation after two cycles without evaluation (one patient), optimal debulking surgery (one patients), baseline iconography > 8 weeks before treatment (one patient), undergoing treatment at cut-off date (one patient). For the 37 patients treated, median response duration was 10.8 months. Six of fifteen responders had received only one prior chemotherapy line, whereas seven and two patients had received two and three lines, respectively. Nine of fifteen responders (60%) had ^ 2 sites involved. Objective responses were observed in 6 of 9 nodal involvement instances, 4 of 10 assessable pelvic sites, and 3 of 7 liver-involvement cases. Six of eighteen platinum-resistant evaluable patients (33%) and 9 of 13 platinum-sensitive evaluable patients (69%) had objective responses. The median PFS in the overall population was 9.4 months (95% CI: 7-12 months). With a 23-month (8-54) median follow-up, there were 19 deaths, with median OS at 25 months (95% CI: 12-39).
Discussion
Resistance to cisplatin and/or carboplatin (primary and acquired) is a major limitation in OC treatment. We investigated whether full recommended doses of paclitaxel could be safely combined with oxaliplatin in platinum-pretreated recurrent OC patients. Haematological toxicity was mild to moderate, easily manageable, and did not require growth-factor support. At the full recommended doses of both agents (DL4), 43% of patients experienced grade 3 and 29% grade 4 neutropenia. Neurosensory neuropathy was frequent, closely correlated with cumulative oxaliplatin doses, but reversible.
Objective responses were seen in half the evaluable patients in all tumour sites. The 10-month response duration, with a PFS of similar length and a long median survival are encouraging, given the pretreatment characteristics.
In two other studies, single-agent high-dose carboplatin was given to patients relapsing after a platinum regimen [10, 11] . Severe haematological toxicity was prevalent, with significant morbidity and a need for growth factors. The reported response rates were 38% [10] , and 57% [11] , but response was defined differently.
There is little data on the paclitaxel/cisplatin or carboplatin combination in cisplatin-carboplatin-pretreated OC [12, 13] . In a recent trial, paclitaxel was given over 24 hours at 135 mg/m 2 with carboplatin (AUC x 5), every 3 weeks, with considerable efficacy (90% ORR) in cisplatin-sensitive patients, although the severe toxicity required G-CSF, and episodes of neutropenic sepsis were frequent. Since paclitaxel-cisplatin is the standard first-line treatment [1] , the oxaliplatin-paclitaxel combination warrants consideration as a viable therapeutic option for relapsing OC patients.
Our data support the effectiveness of oxaliplatin 130 mg/m 2 and paclitaxel 175 mg/m 2 (three hours) administered every three weeks without growth factor support. Many agents show promising activity in pretreated OC patients, but heamatological toxicity limits their usefulness [14, 15] . The prevalence of platinum-sensitive recurring OC patients has increased, and they require active, feasible and well-tolerated second-line regimens. Further clinical studies should be conducted to validate our results with pretreated OC patients, including taxaneexposed patients, before exploring its use in previously untreated patients.
